

CLAIMS LISTING

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a solution of valsartan in methyl t-butyl ether; and
 - b) recovering valsartan amorphous form, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
2. (canceled)
3. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a mixture of water and a solvent selected from the group consisting of ethanol, DMF, acetone and mixtures thereof; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
4. (withdrawn) The process of claim 3, wherein precipitating is carried out by combining water as an anti-solvent with the solution of valsartan in the solvent.
5. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) preparing a solution of valsartan in a solvent selected from the group consisting of tetrahydrofuran, dioxane, ethanol, isopropanol, and diethyl ether; and
 - b) removing the solvent to obtain the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
6. (withdrawn) The process of claim 5, wherein removing is carried out by evaporation.
7. (canceled)
8. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) suspending valsartan in water to obtain amorphous valsartan; and
 - b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.
9. (withdrawn) The process of claim 8, wherein the suspending step includes heating.

10-11. (canceled)

12. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) acidifying a basic aqueous solution of valsartan, wherein the acidifying results in precipitation of amorphous valsartan; and
- b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.

13. (withdrawn) The process of claim 12, wherein the acidifying results in a pH of from about 2 to about 5.

14. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) heating valsartan in diisopropyl ether to obtain amorphous valsartan; and
- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g.

15-80. (canceled)

81. (withdrawn) A pharmaceutical composition comprising amorphous valsartan of claim 17, and a pharmaceutically acceptable excipient.

82. (withdrawn) A method for treating hypertension in a mammal comprising the step of administering the pharmaceutical composition of claim 81 to the mammal in need thereof.

83. (previously presented) Amorphous valsartan having a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

84. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) precipitating amorphous valsartan from a mixture of water and a solvent selected from the group consisting of ethanol, DMF, acetone and mixtures thereof; and
- b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

85. (withdrawn) The process of claim 84, wherein precipitating is carried out by combining water as an anti-solvent with the solution of valsartan in the solvent.

86. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) preparing a solution of valsartan in a solvent selected from the group consisting of tetrahydrofuran, dioxane, ethanol, isopropanol, and diethyl ether; and
- b) removing the solvent to obtain the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

87. (withdrawn) The process of claim 86, wherein removing is carried out by evaporation.

88. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) suspending valsartan in water to obtain amorphous valsartan; and
- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

89. (withdrawn) The process of claim 88, wherein the suspending step includes heating.

90. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) acidifying a basic aqueous solution of valsartan, wherein the acidifying results in precipitation of amorphous valsartan; and
- b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

91. (withdrawn) The process of claim 90, wherein the acidifying results in a pH of from about 2 to about 5.

92. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:

- a) heating valsartan in diisopropyl ether to obtain amorphous valsartan; and
- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram lacks a melting enthalpy above about 1 J/g in region of about 80°C to about 100°C in said DSC.

93. (withdrawn) A pharmaceutical composition comprising amorphous valsartan of claim 83, and a pharmaceutically acceptable excipient.

94. (withdrawn) A method for treating hypertension in a mammal comprising the step of administering the pharmaceutical composition of claim 93 to the mammal in need thereof.

95-96. (canceled)

97. (New) Valsartan purely amorphous, wherein said valsartan is substantially free of crystalline forms of valsartan, and has a halo in the XRPD pattern lacking the peaks or bumps present in the XRPD patterns of Figure 1.

98. (New) The amorphous valsartan of claim 97, having the XRPD pattern as depicted in Figure 2.

99. (New) The amorphous valsartan of claim 97, wherein the valsartan has a melting enthalpy of less than about 1 J/g in the DSC thermogram.

100. (New) The amorphous valsartan of claim 97, wherein the valsartan has a melting enthalpy of less than about 1 J/g in the DSC thermogram, measured in the region of about 80°C to about 100°C.

101. (New) The amorphous valsartan of claim 97, wherein the valsartan has a melting enthalpy of less than about 0.5 J/g in the DSC thermogram, measured in the region of about 80°C to about 100°C.